Background: Salmon calcitonin (sCT) is a polypeptide hormone consisting of 32 amino acid residues (MW approx. 3400 Da), which can be used successfully for the treatment of osteoporosis, Pagefs disease and hypercalcaemia. Only nasal and parenteral preparations of sCT are currently available, and as injections are poorly accepted by patients, nonparenteral preparations for oral, rectal and nasal administration are highly desirable. However, oral sCT is poorly bioavailable, being susceptible to enzymatic degradation in the gastrointestinal tract. Objectives: To design a formulation of sCT suitable for oral use. Method: A water/oil/water (w/o/w) type multiple emulsion formulation was designed for oral application of sCT. sCT was placed in the inner water phase, and a protease inhibitor, aprotinin, was included in the outer water phase of this system to investigate the influence of protease inhibitors in the presence of sCT. The effectiveness of the formulation was evaluated in vitro by placing emulsion samples in a dialysis medium and in vivo by using a rat model. Results: Incorporating sCT in the inner aqueous phase of a w/o/w emulsion appears to protect the peptide from enzymatic degradation. sCT was further protected by incorporating the protease inhibitor, aprotinin, in the outer aqueous phase. Conclusion: w/o/w emulsion formulations appear to be promising carrier systems for peptideprotein drugs.
INTRODUCTION
Multiple emulsions are liquid or semisolid dispersions of a simple emulsion in an external phase. These systems are known to be useful as delivery vehicles for foods, drugs and cosmetics and as solvent reservoirs in drug overdose treatments (1, 2) . More specifically, w/o/w (water-in-oil-inwater) multiple emulsion systems enable the use of two different hydrophilic active materials in separate aqueous phases, and they can therefore be considered as controlled release delivery systems, which .can be used to protect encapsulated substances. The advantages of multiple emulsions as carriers of drugs for oral administration include protection of the drug from enzymatic destruction and enhanced absorption through the intestinal membrane (1, 3, 4) .
The kinetic stability of an emulsion is largely determined by the surfactant film, and the inherently poor stability of multiple emulsions can be improved by optimizing materials and design of the formulation. A number of studies have investigated methods of improving the stability of multiple emulsions (5) (6) (7) . In addition to formulation ingredients, influence of factors such as temperature, equipment, mixing time and speed have also been shown to have an influence (2, (8) (9) (10) .
Oral bioavailability of most peptides and proteins is low because of their susceptibility to the strong acidic environment and the proteolytic enzymes in the gastrointestinal tract. Moreover, peptides and proteins are high molecular weight substances, which do not easily cross the intestinal mucosa and parenteral administration is therefore required to achieve therapeutic effectiveness (11) . However, the parenteral route is the least acceptable route to the patient so there is a need to develop non-parenteral formulations and those with controlled delivery features. Microparticulate drug delivery systems for administration of peptide-protein drugs have been extensively investigated (3, (12) (13) (14) (15) , as have transmucosal (buccal, ocular, nasal, rectal, pulmonary and vaginal mucosa) and transdermal delivery systems (15, 16) .
Caldtonin (CT), an endogenous polypeptide hormone consisting of 32 amino acids, with a molecular weight of 3400 Da, plays a crucial role in both calcium homeostasis and bone remodelling (17) (18) (19) . Four forms of CT are used clinically, synthetic human CT (hCT), synthetic salmon CT (sCT), natural porcine (pCT), and a synthetic analogue of eel calcitonin. Currently CT is administered parenterally or nasally (20, 21) , but given the chronic nature of CT therapy, the oral route would be preferable (22) . SCT is used primarily for the treatment of postmenopausal osteoporosis and Paget's disease and in the management of hypercalcaemia (23, 24) . It has a short biological half-life of approximately 14 min (25) .
The aim of this study was to prepare an oral multiple emulsion formulation of sCT in which the peptide was incorporated into the inner phase and the protease inhibitor, aprotinin, into the outer phase. Using this approach the peptide may be protected from the proteolytic enzymes of the gastrointestinal tract, and improved absorption can therefore be achieved.
METHOD

Materials
Synthetic salmon caldtonin (sCT) 500 mg was donated by Novartis, Turkey, Aprotinin (Tracylol®, 500 000 KIU) by Bayer AC, Germany; Arlacel 1689 and Atlas SCS (lipophilic surfactants) and Synperonic PE/F 127 (hydrophilic surfactants) 127 by ICI surfactants, London. All other reagents used were high performance liquid chromatography (HPLC) grade. Sprague-Dawley female rats were provided by the animal farm of Hacettepe University.
Preparation of the w/o/w multiple emulsion
The general formulation developed for the primary w/o and multiple w/o/w emulsion containing sCT is presented in Table I The w/o/w multiple emulsion formulation was prepared using the twostep emulsification method described by Florence (26) . First a w/o emulsion was prepared using lipophilic surfactants (Arlacel 1689, Atlas SCS 2054) and cholesterol, and then this w/o emulsion was emulsified in a second aqueous phase by means of a hydrophilic surfactant (Synperonic PE/F 127). sCT was included in the inner water phase, whilst aprotinin was incorporated into the outer water phase of the emulsion.
The primary w/o emulsion was mixed using a microvortex homogenizer at a speed of 1200 r.p.m. for 30 min. However, because of the breakdown of multiple droplets in this second step, a lower mixing speed of 500 r.p.m. was used for 10 min. The formulation was prepared at room temperature owing to the instability of sCT at higher temperatures.
Characterization of the w/o/w emulsion
Emulsion samples were evaluated macroscopically by observing homogeneity and phase separation. Microscobical observations were performed using an optical microscope (Nikon, Japan) throughout the study. Photomicrographs of the emulsion samples were taken at 800x magnification and the droplet size distribution was measured with a Laser Diffractometer (Helos Sympatec, Germany). Flow properties of the emulsion samples were determined by a Brookfield DV-II + cone-plate Viscosimeter (U.S.A.) at a constant temperature (25 ± 1 °C), and apparent viscosity and variation against shear stress were recorded. The pH of the emulsion samples were determined against time.
Stability evaluation of the multiple emulsions
The oral multiple emulsions were tested for stability at 4 °C, 25 °C and 40 °C for a period of three months. Changes in droplet size distribution, viscosity, pH and percentage of oil separation over time were determined and the results were used to interpret the stability of the emulsion systems.
Analysis of sCT
sCT was assayed by HPLC using a Biorad C-18 reverse phase column with a gradient pump (Spectra series P 200, U.S.A.). The amount of sCT which diffused through the artificial membrane into the receptor fluid against time was measured by withdrawing samples periodically from the diffusion medium, and sCT content analysed at 220 nm. Deionized water (with trifluoroacetic add 1% A) and acetonitrile (with trifluoroacetic acid 1% B) were used as the mobile phases (18) . The gradient profile was 25-40% B in 7.5 min (23). The injection volume was 10 µL and flow rate was 1 mL/min. The retention time for sCT was 2-4 min.
In vitro diffusion
In vitro diffusion of sCT was determined by placing emulsion samples in a dialysis medium. Diffusion studies were performed in three different media:
phosphate buffer (pH 6.4), simulated intestine solution (pH 7.5), and simulated gastric solution (pH 1.2). Samples of 0.5 ml were withdrawn from the media periodically and replaced by an equal volume of diffusion medium. The amount of sCT present in these samples was measured by HPLC.
In vivo animal model
Twenty-four female Sprague-Dawley rats (four groups) weighing 180-220 g were housed for a period of 4 weeks in proper conditions with appropriate diet. Permission for the experiment was given by the Ethics Committee of Hacettepe University. The drug was administered under ether anaesthesia every other day and formulations were applied orally using a special intragastric drill. A 0.5 mL sample of blood was drawn from the heart of the animals with a syringe, and samples were collected before starting each experiment and then every week throughout the experiment. The samples were centrifuged and levels of calcium determined each week by UV spectrophotometer at 520 nm using an Eppendorf Photometer (27, 28) .
Statistical evaluation
Two-way analysis of variance for repeated measures (ANOVA) of one factor was applied using SPSS 9-0 and the Tukey HSD test was used for pairwise comparisons.
RESULTS AND DISCUSSION
Characterization and stability of the emulsion
The durability of the oil layer can play a significant role in the stability of a multiple emulsion (1) , and in this study we developed a satisfactory w/o/w multiple emulsion of sCT using a two-step emulsification method with a lipophilic surfactant, a lipophilic cosurfactant and cholesterol in the oil phase. These two lipophilic surfactants and cholesterol were used to strengthen the thin oil layer. In the primary w/o emulsion step a microvortex homogenizer was used to provide a fine, homogenous dispersion, as an unstable primary emulsion will led to an unstable multiple emulsion. The characteristics of the multiple emulsion in terms of homogeneity, colour and viscosity were checked by observing multiple droplets under a light microscope (Fig. 1) .
The physical characteristics of the emulsion are shown in Table 2 . The pH of the emulsion samples was checked weekly to control the influence of temperature and storage period on the acidity of the emulsions, but variations were not significant at 4 °C and 25 °C. However, the pH of the samples stored at 40 °C decreased to pH 4. The rheological behaviour of the emulsion was characterized by measuring apparent viscosity and shear thinning. To investigate the effects of temperature and storage time on the flow properties of the emulsion, the apparent viscosity of the samples was also measured at 4 °C, 25 °C and 40 o C. The viscosity of the samples that were stored at 4 °C did not show a significant variation against time and macroscopically gave the best score.
Several approaches have been used to try to overcome the enzymatic degradation of peptides and proteins given by the oral route and encapsulating them in various vehicles and using protease inhibitors appears to be one convenient method (29) (30) (31) . We investigated in vitro permeation of sCT through an artificial membrane (molecular cut-off 10000) in phosphate buffer (pH 6.4), simulated gastric Juice (pH 1.2) and simulated intestinal juice (pH 7-5) by the method we have previously used (32) .
Moreover, we also examined the influence of digestive enzymes by comparing the diffusion behaviour of sCT from solution, multiple emulsion, and multiple emulsion containing aprotinin (Figs 2-4) . In the phosphate buffer medium, the diffused amount of peptide sCT increased by up to 80% at the end of second hour, and diffusion from w/o/w emulsion formulations was better than that from solutions. It is therefore possible to conclude from this data that sCT could be protected from the gastrointestinal environment by incorporating the peptide in the inner phase of a w/o/w emulsion. We obtained similar results with insulin in w/o/w multiple emulsion formulations in our previous study (3) .
In vitro diffusion of sCT from the three different pharmaceutical forms in simulated gastric medium (pH 1.2) proceeded as predicted (Fig. 3) . In the simulated gastric medium, the amount of sCT diffused from the solution form was detected as 20% at the end of first hour of the study. In the presence of gastric peptide (pepsine) proteolytic activity is further inhibited by the inclusion of aprotinin, the w/o/w formulation containing aprotinin apparently produced the best profile, with almost 100°/o of the peptide present in the diffusion medium during the experiment.
As expected, similar results were obtained with the simulated intestine medium (Fig. 4) . Only 10% of the sCT had diffused from the solution form after 30 min of the study. Simulated intestine medium containing trypsin does have a strong proteolytic effect on the peptide, and we attempted to change this by adding aprotinin to the outer phase of the multiple emulsion. Use of this aprotinin-containing formulation resulted in the diffusion of 80% of the sCT into the simulated intestine medium.
In vitro diffusion studies using three different media indicated that w/o/w emulsions seem to protect sCT against proteolytic degradation, and additional protection of sCT was provided by inclusion of a protease inhibitor in the outer water phase of the double emulsion.
These data were supported by in vivo results. Serum calcium levels in the rats were measured each week (Fig. 5) and differences between the formulations were evaluated (Tables 3 and 4) .
Serum calcium levels were compared in general and on a weekly basis using a two-way ANOVA for repeated measures on one factor with SPSS 9.0. With ANOVA, as the interaction term was significant, the differences between consecutive time groups (1st week-initial, 2nd week-lst week and 3rd week2nd week) were calculated and these differences were compared with the results of a one-way ANOVA for the four groups (Tables 5 and 6 ). In case the differences between groups for any of the consecutive time groups were significant, Tukey HSD test was used for pairwise comparisons.
According to the two-way ANOVA for repeated measures: Fig. 5 . Serum calcium levels measured in four rat groups which were administered four different formulations.
• The difference between the four groups (independent of time) was significant (F=3.46, P = 0.036) • The changes in time (independent of the groups) were not significant (F = 1.24, P = 0.302) • The interaction of time and groups was significant, in other words, changes in time were different across the groups (F = 9.64, P = 0.000). One-way ANOVA results for the three consecutive time periods were F= 11.9, P = 0.000; F =4.042, P = 0.021; F = 3.43, P = 0.037 for 1st week-initial, 2nd
week-lst week and 3rd week-2nd week, respectively. In other words, there was a significant difference between the three consecutive time periods across the groups. According to the Tukey HSD test. Group I (control group, base emulsion) was different from the other three groups and a significant difference was found between groups II (aprotinin in sCT formulation) and III (without aprotinin). In addition, when the emulsion formulation III, which contained aprotinin in the outer phase and sCT in the inner phase of the multiple emulsion, was compared with the commercial sCT product (group IV), a similar decrease in the serum caldum levels of the animals was seen throughout the 3-week experimentation period.
Administration of all three sCT-containing multiple emulsion formulations produced a significant hypocalcaemic effect in comparison to the base emulsion formulation (Fig. 5) .
CONCLUSION
Incorporation of the peptide sCT in the inner aqueous phase of a w/o/w emulsion and the protease inhibitor, aprotinin, in the outer aqueous phase appears to protect the peptide from enzymatic degradation, a conclusion that is supported by the fact that this formulation produced similar effects on serum calcium in rats to the commercial formulations, w/o/w emulsion formulations may therefore be promising carrier systems for oral administration of peptide-protein drugs.
